Novel insights and therapeutic interventions for pediatric osteosarcoma

Future directions in the treatment of osteosarcoma

(2016) Michael W. Bishop et al.   CURRENT OPINION IN PEDIATRICS

Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children’s Oncology Group Randomized Trial Pediatric Oncology Group 9404

(2016) Barbara L. Asselin et al.   JOURNAL OF CLINICAL ONCOLOGY

Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma

(2016) Hanneke I. Vos et al.   Pharmacogenetics and Genomics

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma

(2015) A. Gupte et al.   CLINICAL CANCER RESEARCH

Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors

(2015) M. S. Merchant et al.   CLINICAL CANCER RESEARCH

The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?

(2015) Daniel Sanghoon Shin et al.   CURRENT OPINION IN IMMUNOLOGY

Delivering on the promise

(2015) Geraldine OʼSullivan Coyne et al.   CURRENT OPINION IN ONCOLOGY

Immune Checkpoint Inhibitors for Urologic Cancer: The Tip of the Iceberg?

(2015) Tom Powles   EUROPEAN UROLOGY

Can pharmacogenomics help to improve therapy in patients with high-grade osteosarcoma?

(2015) Leo Kager et al.   Expert Opinion on Drug Metabolism & Toxicology

An update on chemotherapy for osteosarcoma

(2015) Stefano Ferrari et al.   EXPERT OPINION ON PHARMACOTHERAPY

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

(2015) Stefan S. Bielack et al.   JOURNAL OF CLINICAL ONCOLOGY

Osteosarcoma: Current Treatment and a Collaborative Pathway to Success

(2015) Michael S. Isakoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration

(2015) Ching-Hon Pui et al.   JOURNAL OF CLINICAL ONCOLOGY

Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions

(2015) Danielle M. Lussier et al.   JOURNAL OF IMMUNOTHERAPY

Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma

(2015) Zuzanna Baranski et al.   JOURNAL OF PATHOLOGY

Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial

(2015) Giovanni Grignani et al.   LANCET ONCOLOGY

Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group

(2015) Saro H Armenian et al.   LANCET ONCOLOGY

Pharmacogenomics in the clinic

(2015) Mary V. Relling et al.   NATURE

Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss

(2015) Heng Xu et al.   NATURE GENETICS

A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis

(2015) Branden S Moriarity et al.   NATURE GENETICS

A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer

(2015) Folefac Aminkeng et al.   NATURE GENETICS

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

RANK Ligand Blockade with Denosumab in Combination with Sorafenib in Chemorefractory Osteosarcoma: A Possible Step Forward?

(2015) Richard Cathomas et al.   ONCOLOGY

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

(2015) E. M. Van Allen et al.   SCIENCE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

RANKL blockade prevents and treats aggressive osteosarcomas

(2015) Yan Chen et al.   Science Translational Medicine

Current treatment strategies for inhibiting mTOR in cancer

(2015) Francesca Chiarini et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency

(2015) Michal Kovac et al.   Nature Communications

Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy

(2015) Rocio K. Rivera-Valentin et al.   PEDIATRIC DRUGS

Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma

(2015) Danielle M Lussier et al.   Journal for ImmunoTherapy of Cancer

Immunotherapy of Childhood Sarcomas

(2015) Stephen S. Roberts et al.   Frontiers in Oncology

Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas

(2015) Jennifer L. Anderson et al.   PLoS One

EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment†

(2014) J. S. Whelan et al.   ANNALS OF ONCOLOGY

Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma

(2014) C. Khanna et al.   CLINICAL CANCER RESEARCH

Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models

(2014) Emmy D.G. Fleuren et al.   INTERNATIONAL JOURNAL OF CANCER

Hyaluronan Synthase 3 Variant and Anthracycline-Related Cardiomyopathy: A Report From the Children's Oncology Group

(2014) Xuexia Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Immune-based therapies for childhood cancer

(2014) Crystal L. Mackall et al.   Nature Reviews Clinical Oncology

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program:PALB2mutation predicts exceptionalin vivoresponse to BMN 673

(2014) Malcolm A. Smith et al.   PEDIATRIC BLOOD & CANCER

Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma

(2014) Katja Goričar et al.   Pharmacogenetics and Genomics

Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma

(2014) Jennifer A. Perry et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma

(2014) Xiang Chen et al.   Cell Reports

Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma

(2013) Michael Roth et al.   CANCER

Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy

(2013) Mahiuddin Ahmed et al.   FEBS LETTERS

Appraising iniparib, the PARP inhibitor that never was—what must we learn?

(2013) Joaquin Mateo et al.   Nature Reviews Clinical Oncology

Emerging patterns of somatic mutations in cancer

(2013) Ian R. Watson et al.   NATURE REVIEWS GENETICS

Cancer Immunotherapy

(2013) J. Couzin-Frankel   SCIENCE

Genome-wide study of methotrexate clearance replicates SLCO1B1

(2012) L. B. Ramsey et al.   BLOOD

Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3

(2012) Hidenobu Shibuya et al.   CANCER SCIENCE

Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells

(2012) Alexander G. Beristain et al.   JOURNAL OF CELL SCIENCE

A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study

(2011) G. Grignani et al.   ANNALS OF ONCOLOGY

Frontline treatment of localized osteosarcoma without methotrexate

(2011) Najat C. Daw et al.   CANCER

Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children

(2011) Henk Visscher et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects

(2010) Katherine A Janeway et al.   LANCET ONCOLOGY

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Review of mifamurtide in the treatment of patients with osteosarcoma

(2010) Leo Kager et al.   Therapeutics and Clinical Risk Management

Sorafenib

(2009) Gillian M. Keating et al.   DRUGS

Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma

(2009) Paul A Meyers   Expert Review of Anticancer Therapy

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways

(2009) Ymera Pignochino et al.   Molecular Cancer

Osteosarcoma: The Same Old Drugs or More?

(2008) Stefan S. Bielack et al.   JOURNAL OF CLINICAL ONCOLOGY

Complexities in Interpretation of Osteosarcoma Clinical Trial Results

(2008) Sally Hunsberger et al.   JOURNAL OF CLINICAL ONCOLOGY

Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

(2008) Paul A. Meyers et al.   JOURNAL OF CLINICAL ONCOLOGY

Second and Subsequent Recurrences of Osteosarcoma: Presentation, Treatment, and Outcomes of 249 Consecutive Cooperative Osteosarcoma Study Group Patients

(2008) Stefan S. Bielack et al.   JOURNAL OF CLINICAL ONCOLOGY